The Allurion Balloon is a regulated health product that bears the CE marking in accordance with this regulation. The indications for use of the Allurion Gastric Balloon System are to promote weight loss in individuals living with excess weight or …

Feb 9, 2023 · Upon closing, the combined company (the “Company”) will be named Allurion Technologies, Inc. and its common stock (the “Common Stock”) is expected to be traded on the New York Stock Exchange under the symbol “ALUR”.

Jan 21, 2025 · The Allurion Program features the Allurion gastric balloon, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for clinicians, and the Allurion Connected Scale and Health Tracker devices.

The Allurion Gastric Balloon and Weight-Loss Program combines medical, digital, and nutritional approaches to help weight loss and form lifelong healthy habits.

BOSTON, MA – July 25, 2023 – Allurion Technologies, Inc. (“Allurion”), a company dedicated to ending obesity, is pleased to announce two major additions to the team.

Oct 11, 2023 · NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the completion of patient enrollment in its AUDACITY trial. AUDACITY is a randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) approval of the Allurion Balloon.

Dec 24, 2024 · Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of Directors has determined to effect a one-for-twenty five reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).

At Allurion, we seek to end obesity globally, helping our patients to live fuller, longer lives. We aim to be the catalyst for weight loss for life. A lasting weight loss program that will guide your weight loss for life.

Aug 1, 2023 · NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion”), a company dedicated to ending obesity, today announced the completion of its previously announced business combination (the “Business Combination”) with Compute Health Acquisition Corp. (“Compute Health”) (NYSE: CPUH), a publicly traded special purpose ...

The indications for use of the Allurion Gastric Balloon System are to promote weight loss in individuals living with excess weight or obesity with a body mass index (BMI) of ≥ 27.0 kg/m2. The Allurion Gastric Balloon System is to be used in conjunction …